HomeProductsBioactive CompoundsMAPK/ERK PathwayRSKLy-2584702
Chemical structure of CAS 1082949-67-4

Ly-2584702

CAS No.1082949-67-4
MDL No.N/A
MFC21H19F4N7
MW445.40
InChI KeyFYXRSVDHGLUMHB-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1082949-67-4
Product NameLy-2584702

Biological Targets

RPS6KB1

Associated Conditions

renal cell carcinoma·cancer·non-small cell lung carcinoma·neuroendocrine neoplasm·metastasis
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.

Journal of clinical pharmacology • Vol. 58, Issue 4 • 2018
PMID: 29178617DOI: 10.1002/jcph.1032

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.

European journal of cancer (Oxford, England : 1990) • Vol. 50, Issue 5 • 2014
PMID: 24456794DOI: 10.1016/j.ejca.2013.12.006

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990) • Vol. 50, Issue 5 • 2014
PMID: 24440085DOI: 10.1016/j.ejca.2013.11.039

Documentation